Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 5 Healthy Participants 5 Breast Neoplasms 5 Prostatic Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Venous Thromboembolism 2 Solid Tumor, Adult 2 Neoplasm Metastasis 2 Healthy Volunteers 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Cardiovascular Diseases 2 cMET-dysregulated Advanced Solid Tumors 1 Venous Thrombosis 1 TP53 Y220C Mutation 1 Stroke 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Sarcoma 1 Rectal Neoplasms 1 Pulmonary Embolism 1 Prostatic Neoplasms, Castration-Resistant 1 Precancerous Conditions 1 Peripheral Nervous System Diseases 1 Pain 1 Ovarian Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Liver Cirrhosis 1 Leiomyosarcoma 1

Interventions

pimodivir 1 Sunitinib 1 Rosuvastatin Calcium 1 Olive Oil 1 Midazolam 1 Interviews as Topic 1 Cyclosporine 1 Control Groups 1 Blood Specimen Collection 1 Adalimumab 1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Healthy × Rosuvastatin Calcium × Clear all

NCT02300363 2015-07-09

DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin

Lexicon Pharmaceuticals

Phase 1 Completed

Healthy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡